Article Text

Download PDFPDF
Recurrent small cell carcinoma of the ovary treated with docetaxel: a case report
  1. S. Niimi*,
  2. T. Kiyokawa,
  3. S. Takakura*,
  4. K. Ochiai* and
  5. T. Tanaka*
  1. *Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
  2. Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan
  1. Address correspondence and reprint requests to: Shigeki Niimi, MD, PhD, Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-19-18 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan. Email: niimi{at}jikei.ac.jp

Abstract

Multiagent chemotherapy for small cell carcinoma of the ovary (SCCO) may contribute to the prolonged survival of young women who are suffering from this disease, even in the advanced stage with remaining tumor, although the rarity of SCCO complicates the generalization of chemotherapy agents and operation methods for this disease. A 24-year-old patient with SCCO FIGO stage IIC is alive after recurrences and chemotherapy including cisplatin + etoposide after the first operation and docetaxel for the second recurrence. She is now doing well with no evidence of disease more than 4 years after the first operation and 2 years after docetaxel treatment. This may be the first report describing the use of docetaxel that may be included in multiagent chemotherapy.

  • combination chemotherapy
  • docetaxel
  • small cell carcinoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.